• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.

    5/15/25 2:04:48 PM ET
    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMNM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Immunome Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    45257U108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45257U108


    1Names of Reporting Persons

    EcoR1 Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,079,415.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,079,415.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,079,415.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  Percentage calculated based on 86,950,655 shares of Common Stock outstanding on March 14, 2025, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    45257U108


    1Names of Reporting Persons

    Oleg Nodelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,079,415.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,079,415.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,079,415.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on 86,950,655 shares of Common Stock outstanding on March 14, 2025, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    45257U108


    1Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,847,477.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,847,477.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,847,477.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on 86,950,655 shares of Common Stock outstanding on March 14, 2025, as reported in the Form 10-K filed by the Issuer for the fiscal year ended December 31, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Immunome Inc.
    (b)Address of issuer's principal executive offices:

    18702 N. Creek Parkway, Suite 100, Bothell, WA 98011
    Item 2. 
    (a)Name of person filing:

    EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13G. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    357 Tehama Street #3 San Francisco, CA 94103
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    45257U108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    EcoR1: 4,079,415 Oleg Nodelman: 4,079,415 Qualified Fund: 3,847,477
    (b)Percent of class:

    EcoR1: 4.7% Oleg Nodelman: 4.7% Qualified Fund: 4.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0

     (ii) Shared power to vote or to direct the vote:

    EcoR1: 4,079,415 Oleg Nodelman: 4,079,415 Qualified Fund: 3,847,477

     (iii) Sole power to dispose or to direct the disposition of:

    EcoR1: 0 Oleg Nodelman: 0 Qualified Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    EcoR1: 4,079,415 Oleg Nodelman: 4,079,415 Qualified Fund: 3,847,477

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    EcoR1 Capital, LLC
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager
    Date:05/15/2025
     
    Oleg Nodelman
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Reporting person
    Date:05/15/2025
     
    EcoR1 Capital Fund Qualified, L.P.
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
    Date:05/15/2025
    Exhibit Information

    Exhibit 99.1 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

    Get the next $IMNM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMNM

    DatePrice TargetRatingAnalyst
    4/2/2025$23.00Buy
    Lake Street
    11/8/2024$30.00Overweight
    Stephens
    5/31/2024$27.00Overweight
    Piper Sandler
    4/30/2024$24.00Overweight
    JP Morgan
    4/15/2024$35.00Buy
    Guggenheim
    1/29/2024$30.00Outperform
    Leerink Partners
    12/19/2023$12.00Outperform
    Wedbush
    10/29/2021$35.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $IMNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Boylan James P

      4 - Immunome Inc. (0001472012) (Issuer)

      6/12/25 5:00:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Schafer Carol

      4 - Immunome Inc. (0001472012) (Issuer)

      6/12/25 4:58:34 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wagenheim Philip

      4 - Immunome Inc. (0001472012) (Issuer)

      6/12/25 4:55:55 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 125,500 shares of common stock to 8 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $8.47

      7/3/25 4:05:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 173,000 shares of common stock to 13 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $9.0

      6/5/25 4:05:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome to Present at Upcoming Investor Conferences

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will participate in the following investor conferences: TD Cowen 6th Annual Oncology Innovation Summit Presentation Date/Time: May 27, 2025, 6:30 a.m. - 7:00 a.m. PT Goldman Sachs 46th Annual Global Healthcare Conference Presentation Date/Time: June 10, 2025, 11 a.m. -11:35 a.m. PT Live webcast links for both presentations will be available on the events tab of Immunome's investor website. Replay links of the presentations will also be available on the website for 30 days following the live broadcast. About Immunome, Inc. Immu

      5/22/25 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Immunome with a new price target

      Lake Street initiated coverage of Immunome with a rating of Buy and set a new price target of $23.00

      4/2/25 8:05:05 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Immunome with a new price target

      Stephens initiated coverage of Immunome with a rating of Overweight and set a new price target of $30.00

      11/8/24 8:17:18 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Immunome with a new price target

      Piper Sandler initiated coverage of Immunome with a rating of Overweight and set a new price target of $27.00

      5/31/24 7:43:20 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Leadership Updates

    Live Leadership Updates

    See more
    • Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

      Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant

      2/11/25 8:30:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Appoints Roee Shahar as Executive Vice President, Commercial

      Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.

      10/8/24 8:05:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

      Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an

      7/9/24 7:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bienaime Jean Jacques bought $46,900 worth of shares (5,000 units at $9.38), increasing direct ownership by 16% to 36,415 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      6/3/25 9:21:39 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bienaime Jean Jacques bought $60,684 worth of shares (7,800 units at $7.78), increasing direct ownership by 33% to 31,415 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:05:21 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Siegall Clay B bought $999,459 worth of shares (137,100 units at $7.29), increasing direct ownership by 20% to 806,736 units (SEC Form 4)

      4 - Immunome Inc. (0001472012) (Issuer)

      3/26/25 4:03:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    SEC Filings

    See more
    • Immunome Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Immunome Inc. (0001472012) (Filer)

      6/11/25 4:01:46 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.

      SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)

      5/15/25 9:01:01 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.

      SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)

      5/15/25 2:04:48 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunome Inc.

      SC 13G/A - Immunome Inc. (0001472012) (Subject)

      11/14/24 9:00:58 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immunome Inc.

      SC 13G - Immunome Inc. (0001472012) (Subject)

      11/14/24 1:28:33 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immunome Inc.

      SC 13G - Immunome Inc. (0001472012) (Subject)

      11/14/24 10:33:51 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMNM
    Financials

    Live finance-specific insights

    See more
    • Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

      Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th

      3/28/24 4:02:00 PM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Third Quarter 2023 Financial Results

      - Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

      11/9/23 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

      Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p

      3/16/23 8:00:00 AM ET
      $IMNM
      Biotechnology: Pharmaceutical Preparations
      Health Care